IDEXX LABORATORIES INC /DE (IDXX)
About IDEXX LABORATORIES INC /DE
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.3B
- Net income
- $1.1B
- Total assets
- $3.4B
- Market cap
- $44.3B
- Gross margin
- 61.8%
- Operating margin
- 31.6%
- Net margin
- 24.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.3B
- Cost of revenue
- $1.6B
- Gross profit
- $2.7B
- Operating expenses
- $1.3B
- Operating income
- $1.4B
- Income tax
- $264.7M
- Net income
- $1.1B
- EPS (basic)
- $13.17
- EPS (diluted)
- $13.08
Balance sheet
- Total assets
- $3.4B
- Current assets
- $1.4B
- Total liabilities
- $1.7B
- Current liabilities
- $1.1B
- Shareholders’ equity
- $1.6B
Cash flow
- Operating cash flow
- $1.2B
- Investing cash flow
- -$136.2M
- Financing cash flow
- -$1.2B
- Net cash flow
- -$108.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $44.3B
- P/E ratio
- 41.6
- EPS (diluted)
- $13.08
- Shares outstanding
- 81.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 1991
Idexx Laboratories Inc /DE (IDXX) Stock Price
- Profitable — net income of $1.1B in FY2025.
- Revenue grew 34% from FY2021 to FY2025.
- Gross margin of 61.8%, net margin 24.6%.
- Trading 29% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 41.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review IDEXX LABORATORIES INC /DE.
Write a review
News about IDEXX LABORATORIES INC /DE
News & sentiment via Polygon.io
Idexx Laboratories Inc /DE: frequently asked questions
Is Idexx Laboratories Inc /DE an American company?
Yes — Idexx Laboratories Inc /DE is an American company headquartered in Westbrook, Maine. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Idexx Laboratories Inc /DE headquartered?
Idexx Laboratories Inc /DE is headquartered in Westbrook, Maine, United States.
Is Idexx Laboratories Inc /DE publicly traded?
Yes — Idexx Laboratories Inc /DE is a publicly traded company. Its stock trades under the ticker symbol IDXX on the NASDAQ.
What does Idexx Laboratories Inc /DE do?
Idexx Laboratories Inc /DE is an American Medical Devices company in the Health & Beauty sector.
